Percentage of women 21-64 years of age, who received one or more Pap tests to screen for cervical cancer.

Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA). 

The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures. 

(c) 2008 -2014 National Committee for Quality Assurance. All Rights Reserved. 

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets.  NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.

CPT(R) contained in the Measure specifications is copyright 2004-2013 American Medical Association. LOINC(R) copyright 2004-2013 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2013 International Health Terminology Standards Development Organisation. ICD-10 copyright 2013 World Health Organization. All Rights Reserved.

These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.
 
Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

None

None

None

Cervical cancer has a high survival rate when detected early, yet it is the second most common cancer among women worldwide (Myers et al. 2008). In the United States, about 12,000 women are diagnosed with cervical cancer each year. In 2010, more than 4,000 women died from cervical cancer (American Cancer Society 2010). For women in whom pre-cancerous lesions have been detected through Pap tests, the likelihood of survival is nearly 100 percent with appropriate evaluation, treatment and follow-up (American Cancer Society 2011). For women under 50 years old, cervical cancer is diagnosed in the early stage 61 percent of the time (American Cancer Society 2010). In 2008, the prevalence of recent Pap test use was lowest among older women, women with no health insurance and recent immigrants (American Cancer Society 2011).

U.S. Preventive Services Task Force (USPSTF) (2003)
Grade: A Recommendation. The USPSTF strongly recommends screening for cervical cancer in women who have been sexually active and have a cervix.
Grade: D Recommendation. The USPSTF recommends against routinely screening women older than age 65 for cervical cancer if they have had adequate recent screening with normal Pap smears and are not otherwise at high risk for cervical cancer.
Grade: D Recommendation. The USPSTF recommends against routine Pap smear screening in women who have had a total hysterectomy for benign disease.
Grade: I Statement. The USPSTF concludes that the evidence is insufficient to recommend for or against the routine use of new technologies to screen for cervical cancer.
Grade: I recommendation. The USPSTF concludes that the evidence is insufficient to recommend for or against the routine use of human papillomavirus (HPV) testing as a primary screening test for cervical cancer.
Kaiser Permanente National Cervical Cancer Screening Guideline Development Team, 2006
Recommendations 1A-D: Effectiveness of Cervical Cancer Primary Screening Tests in Asymptomatic, Average-Risk Women
• Routine cervical cancer screening is recommended for all asymptomatic, average-risk women. (Evidence-based: B)
• Either of the following tests are options for cervical cancer screening in asymptomatic, average-risk women under age 30.
• Conventional cytology (Evidence-based: B)
• Liquid-based cytology (Consensus-based)

Higher score equals better quality.

American Cancer Society. 2011. Cancer Prevention & Early Detection Facts & Figures 2011. Atlanta: American Cancer Society.

Myers, E., K.H. Warner, J.D. Wright, J.S. Smith. 2008. “The current and future role of screening in the era of HPV vaccination.” Gynecologic Oncology 109:S31-S39.

U.S. Preventive Services Task Force. 2003. Screening for cervical cancer: recommendations and rationale. Rockville: Agency for Healthcare Research and Quality.

Kaiser Permanente National Cervical Cancer Screening Guideline Development Team. 2006. Cervical cancer screening guideline. Oakland: Kaiser Permanente Care Management Institute.

American Cancer Society. 2010. Cancer Facts & Figures 2010. Atlanta: American Cancer Society.

None

None

TBD

Women 23-64 years of age with a visit during the measurement period

Equals Initial Patient Population

Women who had a hysterectomy with no residual cervix

Women with one or more Pap tests during the measurement period or the two years prior to the measurement period

Not Applicable

None

Not Applicable

Not Applicable

For every patient evaluated by this measure also identify payer, race, ethnicity and sex.